

Serial No. 10/023,099

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of	: Frank Himmelsbach et al) Docket No.:	5/1310
Serial No.	: 10/023,099) Art Unit:	1624
Filed	: December 17, 2001) Examiner:	Truong, Tamthom Ngo
For	: Quinazoline Derivatives and Pharmaceutical Compositions Containing Them) Confirmation No.:	2352

Mail Stop 313(c)/RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FAX RECEIVED

NOV 08 2004

AMENDMENT**OFFICE OF PETITIONS**

Sir:

This Amendment is being submitted concurrently with a Petition under 37 C.F.R. §1.313(c)(2) and a Request for Continued Examination under 37 C.F.R. §1.114.

Amendments of the Claims are reflected in the listing of claims which begin on page 2 of this paper.

Remarks begin on page 13 of this paper.


Serial No. 10/023,099

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of Claims:

1. (previously presented) A compound of general formula I



wherein:

R_a is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group;

R_b is a dimethylamino, *N*-methyl-*N*-ethylamino, *N*-methyl-*N*-isopropylamino, *N*-methyl-*N*-cyclopropylamino, *N*-methyl-*N*-(2-methoxyethyl)amino, *N*-ethyl-*N*-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, *N*-methyl-*N*-(tetrahydrofuran-3-yl)amino, *N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino, *N*-methyl-*N*-(tetrahydrofuran-3-ylmethyl)amino, *N*-methyl-*N*-(tetrahydropyran-4-yl)amino, or *N*-methyl-*N*-(tetrahydropyran-4-ylmethyl)amino group; and

R_c is a cyclopropylmethoxy, cyclobutylloxy, cyclopentylloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a stereoisomer or physiologically acceptable salt thereof.

2. (previously presented) The compound of claim 1, with the exception of the compounds:

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;

Serial No. 10/023,099

- (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;
- (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutylloxyquinazoline;
- (4) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentylloxyquinazoline;
- (5) 4-[(*R*)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutylloxyquinazoline;
- (6) 4-[(*R*)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline;
- (7) 4-[(*R*)-(1-phenylethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentylloxyquinazoline;
- (8) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (9) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-ethyl-*N*-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (10) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydropyran-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (11) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline; and
- (12) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline,

or a stereoisomer or physiologically acceptable salt thereof.

Serial No. 10/023,099

3. (previously presented) The compound of one of claims 1 or 2, with the exception of the compounds:

- (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-cyclopropylmethoxyquinazoline;
- (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{{4-(dimethylamino)-1-oxo-2-buten-1-yl}amino}-7-cyclopropylmethoxyquinazoline;
- (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-{{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-cyclobutyloxyquinazoline;
- (4) 4-[(3-chloro-4-fluorophenyl)amino]-6-{{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-cyclopentyloxyquinazoline;
- (5) 4-[(*R*)-(1-phenylethyl)amino]-6-{{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-cyclobutyloxyquinazoline;
- (6) 4-[(*R*)-(1-phenylethyl)amino]-6-{{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-cyclopropylmethoxyquinazoline;
- (7) 4-[(*R*)-(1-phenylethyl)amino]-6-{{4-(morpholin-4-yl)-1-oxo-2-buten-1-yl}amino}-7-cyclopentyloxyquinazoline;
- (8) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (9) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-ethyl-*N*-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (10) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydropyran-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;

Serial No. 10/023,099

- (11) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (12) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (13) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-(2-methoxyethyl)-*N*-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxyquinazoline;
- (14) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline;
- (15) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline;
- (16) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(*S*)-*N*-methyl-*N*-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline;
- (17) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(*R*)-*N*-methyl-*N*-(tetrahydrofuran-3-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline;
- (18) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(tetrahydropyran-4-yl)amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxyquinazoline;
- (19) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(*R*)-*N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxyquinazoline;
- (20) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(*S*)-*N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxyquinazoline;
- (21) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-3-yloxy)quinazoline;

Serial No. 10/023,099

(22) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydropyran-4-yloxy)quinazoline;

(23) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[*N*-methyl-*N*-(2-methoxyethyl)amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-2-ylmethoxy)quinazoline; and

(24) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(*N*-cyclopropyl-*N*-methylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxyquinazoline,

or a stereoisomer or physiologically acceptable salt thereof.

4. (previously presented) The compound of general formula I according to claim 1, wherein:

R_a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group;

R_b is a dimethylamino, *N*-methyl-*N*-ethylamino, *N*-methyl-*N*-isopropylamino, *N*-methyl-*N*-cyclopropylamino, *N*-methyl-*N*-(2-methoxyethyl)amino, *N*-ethyl-*N*-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, *N*-methyl-*N*-(tetrahydrofuran-3-yl)amino, *N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino, *N*-methyl-*N*-(tetrahydrofuran-3-ylmethyl)amino, *N*-methyl-*N*-(tetrahydropyran-4-yl)amino, or *N*-methyl-*N*-(tetrahydropyran-4-ylmethyl)amino group; and

R_c is a cyclopropylmethoxy, cyclobutylloxy, cyclopentylloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a stereoisomer or physiologically acceptable salt thereof.

5. (previously presented) The compound of general formula I according to claim 2, wherein:

R_a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group;

R_b is a dimethylamino, *N*-methyl-*N*-ethylamino, *N*-methyl-*N*-isopropylamino, *N*-methyl-*N*-cyclopropylamino, *N*-methyl-*N*-(2-methoxyethyl)amino, *N*-ethyl-*N*-(2-methoxyethyl)amino,

Serial No. 10/023,099

bis(2-methoxyethyl)amino, morpholino, *N*-methyl-*N*-(tetrahydrofuran-3-yl)amino, *N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino, *N*-methyl-*N*-(tetrahydrofuran-3-ylmethyl)amino, *N*-methyl-*N*-(tetrahydropyran-4-yl)amino, or *N*-methyl-*N*-(tetrahydropyran-4-ylmethyl)amino group; and

R_c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a stereoisomer or physiologically acceptable salt thereof.

6. (previously presented) The compound of general formula I according to claim 3, wherein:

R_a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group;

R_b is a dimethylamino, *N*-methyl-*N*-ethylamino, *N*-methyl-*N*-isopropylamino, *N*-methyl-*N*-cyclopropylamino, *N*-methyl-*N*-(2-methoxyethyl)amino, *N*-ethyl-*N*-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, *N*-methyl-*N*-(tetrahydrofuran-3-yl)amino, *N*-methyl-*N*-(tetrahydrofuran-2-ylmethyl)amino, *N*-methyl-*N*-(tetrahydrofuran-3-ylmethyl)amino, *N*-methyl-*N*-(tetrahydropyran-4-yl)amino, or *N*-methyl-*N*-(tetrahydropyran-4-ylmethyl)amino group; and

R_c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group,

or a stereoisomer or physiologically acceptable salt thereof.

Cancel claims 7 to 20.


Serial No. 10/023,099

REMARKS

Claims 7 to 20 have been canceled. Claims 1 to 6 are pending. Applicants respectfully submit that this application remains allowable for the reasons clearly set forth in the Notice of Allowance dated July 29, 2004.

If the Examiner feels that a telephone interview would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Respectfully submitted,



Susan K. Pocchiari
Attorney for Applicant(s)
Reg. No. 45,016

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 798-4866
Fax: (203) 798-4408
Date: November 8, 2004

*** RX REPORT ***

RECEPTION OK

TX/RX NO	7662
RECIPIENT ADDRESS	
DESTINATION ID	
ST. TIME	11/08 12:31
TIME USE	04'39
PGS.	15
RESULT	OK